STICH-3.0 International Trial Consortium

Summary

The primary objective of the STICH 3.0 Study is to determine whether CABG is superior to PCI in terms of all-cause mortality at 5 years in patients with severe CAD and iLVSD.

Individual patient data from similar national RCTs independently powered for different efficacy endpoints will be pooled, harmonized, and analyzed.

The primary endpoint is all-cause mortality.

Conditions

• Coronary Artery Disease
• Heart Failure

Interventions

PROCEDURE

Percutaneous Coronary Intervention (PCI)

Alternative treatment

Sponsors & Collaborators

• University of Glasgow

  collaborator OTHER

• Yale University

  collaborator OTHER

• University of Oxford

  collaborator OTHER

• University of Leicester

  collaborator OTHER

• University of Toronto

  collaborator OTHER

• Université de Montréal

  collaborator OTHER

• Curtin University

  collaborator OTHER

• Monash University

  collaborator OTHER

• Jena University Hospital

  collaborator OTHER

• Hannover Medical School

  collaborator OTHER

• University of Groningen

  collaborator OTHER

• University of Copenhagen

  collaborator OTHER

• Weill Medical College of Cornell University

  collaborator OTHER

• Vastra Gotaland Region

  lead OTHER_GOV

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-09-14

Primary Completion

2029-09-14

Completion

2029-09-14

Countries

• Sweden

Study Locations